Background/aims: The timing of GpIIb/IIIa inhibitor administration may be important in achieving early epicardial and myocardial reperfusion. We evaluated the effect of early tirofiban on myocardial salvage and cardiovascular outcome in patients with acute myocardial infarction (AMI) undergoing infarct-related artery stenting.
Methods: Patients (n = 66) with a first AMI presenting <6 h from onset of symptoms were randomized to either early administration of tirofiban in the emergency room (n = 32) or later administration in the catheterization laboratory (n = 34) (tirofiban bolus dose of 10 microg/kg, followed by 0.15 microg/kg for 24 h). The primary end-point was the degree of myocardial salvage, determined by means of serial scintigraphic studies with technetium-99m sestamibi. Thirty-day major adverse cardiac events were also assessed.
Results: There were no significant differences in patient characteristics or in their presentation. The mean door-to-balloon time was similar in both groups (43 +/- 12 and 53 +/- 9 min, p = 0.08). The early and late treatment groups received tirofiban 18 +/- 4 and 52 +/- 10 min after admission, respectively. Angiographic analysis revealed a higher initial frequency of TIMI grade 3 flow in the early group (31% vs. 12%, p = 0.04). Procedural success was achieved in all patients. Myocardial risk area were comparable between early and late treatment groups (35.6 +/- 12.2% vs. 39.3 +/- 14.0%, p = 0.6). Scintigraphic outcomes demonstrated a significant reduction in the final infarction size (11.8 +/- 5.2% vs. 22.4 +/- 6.2%, p = 0.01), and improvement in salvage index (0.68 +/- 0.22 vs. 0.44 +/- 0.18, p = 0.003) in favor of the early tirofiban group. The thirty-day composite end-point of death, recurrent MI or rehospitalization also favored the early group (6% early, 15% late, p = 0.06).
Conclusion: Early tirofiban administration enhanced the degree of myocardial salvage and clinical outcome in patients with AMI undergoing infarct-related artery stenting.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1159/000093408 | DOI Listing |
Clin Neurol Neurosurg
December 2024
Department of Neurology, the Third Affiliated Hospital of Wenzhou Medical University, Ruian, Zhejiang Province, China. Electronic address:
Objective: Tirofiban is an effective treatment for ischemic stroke that is frequently used following early neurological deterioration (END). However, studies investigating the effects of tirofiban on patients with posterior circulation stroke (PCS) are scarce. Thus, this study aimed to explore factors affecting the outcomes of tirofiban in PCS.
View Article and Find Full Text PDFBiomed Mater
November 2024
Beijing Anzhen Hospital Affiliated to Capital Medical University, Coronary Heart Disease Surgery Center Zone 1, Beijing, People's Republic of China.
Early thrombosis following coronary artery bypass grafting (CABG) surgery leads to perioperative myocardial infarction, which causes difficulties for clinicians and patients. Moreover, once perioperative myocardial infarction occurs, the mortality rate is extremely high. In recent years, microneedle (MN) drug delivery systems have become a research hotspot with broad clinical application prospects.
View Article and Find Full Text PDFInt J Stroke
November 2024
Department of Neurology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, China.
Background: Intravenous thrombolysis (IVT) is the cornerstone treatment for the acute ischemic stroke (AIS) within 4.5 h after onset. Current guidelines recommend administering antiplatelet medications 24 h after IVT.
View Article and Find Full Text PDFSci Rep
November 2024
Department of Diagnostic and Interventional Neuroradiology, University Hospital RWTH Aachen, Aachen, Germany.
The glycoprotein IIb/IIIa antagonist tirofiban has been shown to prevent thromboembolic events during endovascular procedures, but the benefits and risks of its prophylactic early intraprocedural administration for stand-alone coil embolization of acutely ruptured aneurysms are still unclear. We conducted a retrospective single-center analysis of patients treated for aneurysmal subarachnoid hemorrhage with stand-alone coil embolization. Two study cohorts were compared according to the primary prophylactic antithrombotic medication during the procedure: patients receiving only intravenous heparin (HEP) versus patients receiving tirofiban in addition to heparin prior to final aneurysm obliteration (HEP + TF).
View Article and Find Full Text PDFAsian J Surg
October 2024
Department of Neurology, Shaanxi Provincial People's Hospital, Xi'an, Shaanxi, China. Electronic address:
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!